Piper Sandler Maintains Overweight on Sutro Biopharma, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Sutro Biopharma (NASDAQ:STRO) but reduced the price target from $18 to $12.
November 15, 2023 | 3:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler has maintained an Overweight rating on Sutro Biopharma but has lowered the price target from $18 to $12.
The reduction in price target by Piper Sandler, despite maintaining an Overweight rating, could lead to a negative perception among investors, potentially causing a short-term decline in STRO's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100